TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis.
CONCLUSION: TRIB3 promotes growth abilities of HCC cells both in vitro and in vivo and predicts poor prognosis of HCC patients, which serves as a prognostic marker and might provide a potential therapeutic candidate for patients with HCC.
PMID: 32716348 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Hepatocellular Carcinoma | Kidney Cancer | Liver Cancer | Lung Cancer | Renal Cell Carcinoma